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Abstract
Background. Mobility is a key determinant of frailty in older persons, and a variety of 
dietary factors, such as the omega-3 fatty acid docosahexaenoic acid (DHA), are posi-
tively associated with decreased frailty and improved mobility and cognition in older 
persons.
Methods. The effects of a multinutrient supplement on mobility and cognition were 
assessed in postmenopausal women (60–84 years). Participants received either Efalex 
Active 50+ (1 g DHA, 160 mg eicosapentaenoic acid, 240 mg Ginkgo biloba, 60 mg 
phosphatidylserine, 20 mg d-α tocopherol, 1 mg folic acid, and 20 µg vitamin B12 per 
day; N  =  15) or placebo (N  =  12) for 6  months. Mobility was assessed by VICON 9 
motion capture camera system synchronized with Kistler force plates, cognitive per-
formance by computerized cognitive function tests, and blood fatty acid levels by 
pin-prick analysis.
Results. Significant effects of treatment were seen in two of the four cognitive tests, with 
shorter mean latencies in a motor screening task (p < .05) and more words remembered 
(p < .03), and one of the three primary mobility measures with improved habitual walk-
ing speed (p < .05). Compared with the placebo group, supplementation also resulted in 
significantly higher blood DHA levels (p < .02).
Conclusions. In this pilot study, multinutrient supplementation improved cognition and 
mobility in able older females at clinically relevant levels, suggesting a potential role in 
reducing the decline to frailty.
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There is a complex relationship between cognition and 
mobility, whereby a decline in gait performance coexists 
with or precedes onset of cognitive decline in older persons 
(1). Interventions targeting cognition improve mobility (1) 
and improvements in mobility predict reduced mortality (2). 
Given the increased social and economic burden of a frail 
aging population, it is important to identify lifestyle inter-
ventions able to preserve mobility and cognition. A number 
of dietary factors may represent such interventions includ-
ing omega-3 polyunsaturated fatty acids (PUFAs), vitamin 
E, phosphatidylserine, B vitamins, and Ginkgo biloba.
The omega-3 PUFAs docosahexaenoic acid (DHA) 
and eicosapentaenoic acid (EPA) may confer benefits in 
neurodegenerative conditions (3) and mobility in older 
persons (4). Elevated levels of vitamin E (α-tocopherol) 
are associated with reduced risk of cognitive impair-
ment in older persons (5); however, clinical trials have 
failed to demonstrate benefits (6). This dissonance may 
be due to the predominant role of α-tocopherol being 
supportive, protecting PUFAs, particularly DHA, in 
membranes (7). PS supplementation may benefit cogni-
tion in the elderly populations (8). Membrane DHA is a 
positive modulator of PS biosynthesis, and it is unclear 
whether the beneficial effects of PS are due to intact 
PS or DHA released following hydrolysis (9). Elevated 
plasma homocysteine is a risk factor for brain atrophy 
and cognitive decline, and treatment with B vitamins 
reduces brain atrophy and may slow cognitive decline 
(10). Interestingly, recent evidence suggests an impor-
tant interaction between B vitamins and DHA in the 
cognitively impaired elderly populations (11). Ginkgo 
biloba is a widely studied herbal extract for cognitive 
impairment, and although evidence of clinical benefits 
is inconsistent, a recent meta-analysis indicates it may 
slow cognitive decline (12).
A recent review highlights the importance of taking a 
more holistic approach to research into nutrition and brain 
aging, exploring potential synergies between nutrients as 
found in a balanced diet (13). Taking this approach, the 
main objective was to identify whether a commercially 
available preparation containing a range of dietary factors 
indicated to improve cognition (DHA, EPA, Ginkgo biloba, 
PS, α-tocopherol, folic acid and vitamin B12) improves 
cognition and mobility in able older females. Preliminary in 
vitro evidence in our laboratory suggests that this specific 
combination of nutrients may have synergistic neuropro-
tective and anti-inflammatory properties (M. Sakthithasan, 
PhD, R.E. Ward, PhD, Michael-Titus, Doct en Sci, P. Clough, 
MSc, unpublished data, 2008). Secondary objectives were 
to explore the nature of the relationship between DHA lev-
els and these outcomes, since DHA is a major unifying fac-
tor in the effects of many of these nutrients.
Methods
See Supplementary Material for detailed methodology.
Participants
A stratified block randomization design matching the num-
ber of nonfrail, prefrail, and frail participants between 
groups was used. Randomization was performed using an 
online sample generator and frailty classified by pheno-
type (14). All analyses were conducted at the University of 
Roehampton, London, UK, which granted ethical approval. 
All participants provided written informed consent. All 
outcome measures were collected at baseline and 6 months 
by a research assistant, who along with the participants 
was blinded to the intervention groups.
Nonacutely ill females aged 60 and older were recruited 
and screened by the following criteria: community dwell-
ing, able to walk at least 50 m, and negotiate stairs inde-
pendently. Exclusion criteria were vestibular impairments, 
neurological disorder, lower limb surgery, allergy to sea-
food, or regular consumption of multivitamin/fish oil 
supplements. Subjects were recruited by invitation from 
existing databases, and community presentations to senior 
centers and community groups.
Intervention
Participants received four capsules per day of Efalex Active 
50+ (N = 15) or placebo (N = 12) throughout the 24-week 
study. The intervention provided 1 g DHA and 160 mg EPA 
per day in addition to Ginkgo biloba, PS, α-tocopherol, folic 
acid, and vitamin B12 (See Supplementary Table S1). The 
control group received capsules containing an isocalorific oil 
blend matched to the composition of the typical fat content of 
an average diet. Participants were told to take their daily sup-
ply of capsules with their largest meal of the day. The capsules 
were counted, coded, and allocated by the principal investi-
gator, who was not involved in the assessment. Compliance 
was measured by changes in DHA levels compared to base-
line, counting returned pills at the mid-point and end of the 
study, and exit questionnaire. Adverse events were monitored 
by subject self-reporting and exit questionnaire.
Outcome Measures
The primary outcome measures were based on changes in 
mobility and cognition. Habitual walking (HW) speed is a 
sensitive measure of overall health and function and recom-
mended as a primary outcome in interventions on elderly 
populations (15). In older people, faster habitual and maxi-
mal gait speed predicts increased longevity (16). Therefore, 
both HW and fast walking (FW) speed were included as 













primary outcomes. Vertical jump height (VJH) has been 
studied to assess the body’s ability to rapidly produce force 
in a coordinated manner (17) and was also included as a 
primary mobility outcome. The importance of information 
processing speed (18) and executive function (19) in gait 
has consistently been shown; however, associations with 
memory decline have also been identified (19). Therefore, 
psychomotor response latency (MOT) as an index of 
information processing speed, executive function, Verbal 
Recognition Memory (VRM), and paired associate learn-
ing (PAL) were primary cognitive outcomes.
In order to identify potential mechanisms behind 
improvements in gait speed, cadence and stride length were 
included as secondary outcomes. The relationship between 
blood DHA status (DHA levels and ratio of the omega-6 
fatty acid, arachidonic acid [AA] to DHA [AA:DHA]) and 
cognitive and mobility outcomes at baseline and at the 
end of the study were also included as further secondary 
outcomes.
Mobility
HW and FW speed, cadence and step length and VJH were 
analyzed using a nine camera VICON system integrated 
with two Kistler force plates. The mean of five trials was 
taken for gait, whereas the best of three maximal jumps 
was analyzed for VJH. Speed, cadence, and step length 
were calculated using Nexus software (Version 1.8.5, 
Oxford Metrics Group, UK). VJH was calculated as the 
height (mm) of the pelvis during static standing subtracted 
from the highest vertical displacement during flight.
Cognition
A battery of computer-based cognitive tests (CANTAB, 
Cambridge Cognition Ltd.) was performed. Psychomotor 
response latency ‘motor screening task’ (MOT), two mem-
ory tests (VRM) and (PAL), and one executive function test 
(Stockings of Cambridge) were analyzed.
Blood Fatty Acid Analysis
Fingertip pin-prick blood samples were collected to analyze 
fatty acid composition using a previously validated method on 
nonfasted subjects (20). Individual fatty acids were identified 
by gas chromatography coupled with flame ionization detec-
tor (Agilent technologies, USA), as described previously (21).
Statistical Analysis
Results are reported according to the CONSORT statement 
(22). Groups were compared at baseline by student’s t test 
for two independent samples or Freeman-Halton extension 
of the Fisher exact probability test. Associations between 
cognition, mobility, and DHA status were examined using 
Pearson’s partial correlations, controlling for age. National 
Adult Reading Test score was also included as a covariate 
in preliminary analysis, but as it did not influence results, 
it was excluded in final models. DHA levels and mobility 
were further explored at baseline by multiple regression, 
with DHA the predictor variable and age, body mass index, 
physical activity, and grip strength included. Correlation 
and regression data were examined to ensure assumptions 
were not violated. For the regression analyses, a sample size 
of 29 was required to achieve a power of 0.80 for a correla-
tion coefficient of 0.50 and an α of 0.05, for a two-tailed 
test (23).
Treatment effects were analyzed by general linear 
model and analysis of variance on cognition and mobility 
from the final session with baseline data and age as covari-
ates and were calculated based on differences between the 
treatment groups adjusted mean values. Due to the pre-
liminary nature of the study, sample size was determined 
based on HW speed, where meaningful differences of 
between 0.05 and 0.08 m/s have been suggested (24,25). 
The sample size calculation was therefore based on a dif-
ference of 0.07 m/s with a power of 0.8 and an α of 0.05 
(one-tailed test). A minimum sample size of 17 participants 
per group was required to detect an effect size d of 0.8 
(G*Power 3.1.10) (26). In all analyses, p < .05 was con-
sidered significant, and there was no multiple-test adjust-
ment of p values to avoid Type-II errors, as recommended 
(27). One-tailed p values are given where the direction was 
predicted by the hypotheses, otherwise two-tailed values 
are given. Statistical analyses were performed using IBM 
SPSS statistics version 21 (Chicago, Illinois). All results are 
expressed as means (SD).
Results
Participants
Participant flow is shown in Figure 1. In total, 12/14 of the 
placebo group and 15/15 of the intervention group com-
pleted the study. One subject moved prior to allocation and 
another was diagnosed with a medical condition excluding 
them from analysis. Analyses were conducted on those who 
completed the study with no exclusions irrespective of com-
pliance or protocol violations. For baseline characteristics, 
see Supplementary Table S2. There were no reported side 
effects in either group during the study. Compliance meas-
ured by changes in blood DHA levels was 66.7% in both 
groups, whereas compliance measured by capsule counts 
was higher and also not significantly different between 
groups (placebo, 86.1% [12.3%] and intervention, 89.8% 













[15.1%]). None of the participants reported changing their 
physical activity or diet during the study.
Primary Outcome Measures
Effects of treatment on cognition and mobility
The significant effects of 6 months mixed multinutrient 
supplementation versus placebo on cognition and mobil-
ity are summarized in Table 1. The intervention resulted 
in significantly shorter MOT mean latencies to touch 
compared with placebo [F(1,23) = 3.47, p =  .038, one-
tailed], with a mean adjusted difference between groups 
of 118 ms and medium effect size (ηp
2  =  0.13). There 
were no significant effects on MOT mean errors (touch 
accuracy). In the VRM test, the intervention resulted 
in significantly more words immediately remembered 
compared with placebo [F(1,23) = 4.00, p =  .029, one-
tailed], with a mean adjusted difference of 1.3 words out 
of a maximum of 12 and medium effect size (ηp
2 = 0.15). 
The intervention had no effects on the total number 
of words recognized after 20 min delay or on PAL or 
Stockings of Cambridge tests. The intervention resulted 
in a significant improvement in HW speed compared to 
placebo [F(1,23) = 3.88, p = .031, one-tailed], with mean 
adjusted difference of 0.07 m/s and medium effect size 
(ηp
2 = 0.14). There were no significant treatment effects 
on FW speed or VJH.
Secondary Outcome Measures
Effects of treatment on gait parameters
There were no significant effects of treatment on cadence or 
stride length for HW or FW, summarized in Table 2. 
Fatty acid analysis
At baseline, age was significantly associated with lower lev-
els of total omega-3 PUFAs, (Pearson correlation −0.431, 
p  =  .025), EPA (−0.462, p  =  .015), and DHA (−0.436, 
p  =  .023). Therefore, age was included as a covariate in 
all analyses. There were no significant differences between 
groups at baseline for any fatty acid. Following supplemen-
tation, the intervention group showed significant increases 
in DHA of 17% [F(1,23)  =  6.52, p  =  .018] and EPA of 
71% [F(1,23) = 11.66, p < .002] and decreases in AA of 
Figure 1. CONSORT diagram reflecting flow of study participants through the study.













18% [F(1,23) = 6.99, p < .015] compared with the placebo 
group, adjusted for age and baseline values. There were no 
significant effects of treatment on AA:DHA or other fatty 
acids.
Baseline correlations
Partial correlations (Table 3) identified significant associa-
tions between DHA levels and all measures of mobility, and 
AA:DHA was significantly associated with both HW and 
FW speeds. There were also trends for associations between 
DHA and AA:DHA and grip strength, p < .062 and p < 
.067, respectively. There were no significant correlations 
between DHA or AA:DHA and cognition, or between cog-
nition and mobility. All mobility outcomes were highly cor-
related with each other, whereas there were no significant 
correlations between cognitive tests.
When the predictor variables were modeled together by 
multiple regression for HW speed, there were no significant 
effects of body mass index, age, or grip strength. DHA and 
Physical Activity Scale of the Elderly remained significant 
following adjustments, explaining 47% of the variance 
(adjusted R2 = .469; Table 4). Similarly, for FW speed, DHA 
and Physical Activity Scale of the Elderly also remained 
significant, explaining 41% of the variance (Adjusted 
R2 = .412). With VJH there were significant effects of age, 
DHA and body mass index after adjustments, explaining 
65% of the variance (Adjusted R2 = .646).
The relationships between changes in DHA status and 
changes in cognition and mobility at the end of the study 
were investigated and are shown in the Supplementary 
Material and Supplementary Table 3.
Discussion
This pilot study shows for the first time that a multinu-
trient supplement significantly improves some measures of 
cognition and mobility in able older females. There were 
significant improvements in the two of the four cognitive 
tests (MOT and VRM) and one of the three primary mobil-
ity measures (HW speed), all with medium effect sizes. 
Table 1. Effects of Treatment on Cognition and Mobility
Variable Baseline Mean (SD) Six Months Mean (SD) Adjusted Mean (SD) p Value
Cognition
 MOT latency (ms)
  Placebo 1171 (276) 1162 (180) 1170 (162) .038
  Intervention 1171 (275) 1058 (190) 1052 (162)
 VRM immediate free recall (words)
  Placebo 9.2 (1.7) 8.0 (2.2) 7.7 (1.7) .029
  Intervention 8.7 (2.3) 8.8 (2.1) 9.0 (1.7)
Mobility
 HW Speed (m/s)
  Placebo 1.35 (0.20) 1.32 (0.15) 1.29 (0.08) .031
  Intervention 1.30 (0.24) 1.33 (0.25) 1.36 (0.10)
Note: FW = fast walking; HW = habitual walking; MOT = motor screening task; VJH = vertical jump height; VRM = verbal recognition memory.
Table 2. Effects of Treatment on Cadence and Stride Length
Variable Baseline Mean (SD) Six Months Mean (SD) Adjusted Mean (SD) p Value
HW cadence (steps/min)
 Placebo 116.3 (6.9) 114.8 (5.2) 113.7 (4.8) .118
 Intervention 114.1 (8.8) 115.1 (10.4) 116.0 (4.8)
HW stride length (m)
 Placebo 1.38 (0.14) 1.38 (0.12) 1.36 (0.06) .064
 Intervention 1.35 (0.21) 1.38 (0.21) 1.39 (0.05)
FW cadence (steps/min)
 Placebo 134.9 (6.0) 134.5 (7.3) 130.3 (7.6) .065
 Active 130.3 (7.0) 131.7 (13.9) 135.1 (7.6)
FW stride length (m)
 Placebo 1.53 (0.15) 1.48 (0.22) 1.47 (0.12) .100
 Intervention 1.53 (0.24) 1.53 (0.24) 1.53 (0.12)
Note: FW = fast walking; HW = habitual walking.













Furthermore, lower circulating DHA was associated with 
poorer mobility, and increasing DHA was positively associ-
ated with improvements in walking speeds. However, due 
to the lack of statistical power, these observations can only 
be considered preliminary.
The improvements in verbal memory are consistent with 
previous reports of positive effects with DHA (900 mg/d) 
on VRM (28). However, this group reported improvements 
with immediate and delayed word recognition, rather than 
free recall. They also found significant improvements in the 
PAL memory test (six pattern errors). The differences may 
be due to different abilities between the study participants. 
In their study, the participants performed at much lower 
levels, and our participants may have suffered from ceiling 
effects, for example, our participants recognized 11.5 of 12 
target words on average. Indeed, a mean of 9.0 words for 
immediate recall is more consistent with a much younger 
age range (29).
Improvements in psychomotor response latency (MOT) 
were also seen following treatment. Previous studies with 
either omega-3 PUFAs (30) or folic acid and vitamin B12 
(31) supplementation have failed to provide evidence of 
beneficial effects on information processing speed in older 
adults. However, beneficial effects have been reported in 
younger adults (32), and it may be that the synergistic com-
bination of nutrients found in the multinutrient supple-
ment has a greater effect than individual nutrients in older 
persons.
The treatment significantly improved HW speed. 
Maintaining walking speed in old age is clinically impor-
tant as speed is a risk factor for cognitive impairment, falls, 
and mortality (15). Our participants were extremely fit at 
baseline (15), but significant improvements were still seen. 
The difference in adjusted mean scores represented a 0.07 
m/s improvement between groups, reflecting clinically rel-
evant improvements (25). Contributing to the effects were 
decreases in the average speed of the placebo group slightly 
greater than would be predicted (33) and improvements in 
the intervention group. There was no single factor driving 
the improvements as there were trends for improvements in 
both stride length and cadence.
No significant effects were observed with FW speed or 
VJH. The placebo group maintained their FW speed over 
the study, contrary to expectations (34), which may have 
mitigated treatment effects. Jump height variability is high 
in older people (35) as this is a novel task, consistent with 
physical activity not being a predictor in the regression 
analysis. The balance between fatigue and potential injury 
Table 3. Pearson’s Partial Correlations Between DHA Status, Mobility, and Cognition at Baseline








DHA −.892*** .372 .465** .552*** .498*** .049 −.161 .055 .033
AA:DHA −.364 −.538*** −.618*** −.337 −.092 .217 .089 −.012
Grip (kg) .148 .265 .198 .175 −.095 .184 .056
HWS (m/s) .877*** .493*** −.066 .099 −.206 .160
FWS (m/s) .552*** .124 .116 .050 .222
VJH (mm) .003 .039 .049 .378
MOT† (ms) .348 −.243 −.052
VRM‡ .151 .160
PAL§ .169
Notes: AA = arachidonic acid; DHA = docosahexaenoic acid; FWS = fast walking speed; Grip = grip strength; HWS = habitual walking speed; MOT = motor 





**p < .05, ***p < .01.
Table 4. Multiple Regression Models Showing Significant 
Associations With Mobility at Baseline




 DHA (wt%) 0.102 0.041, 0.162 .002
 PASE score 0.003 0.001, 0.004 .001
FW Speed (m/s)
 PASE score 0.002 0.000, 0.004 .047
 DHA (wt%) 0.141 0.069, 0.214 <.001
VJH (mm)
 Age (y) −0.319 −0.541, −0.098 .007
 DHA (wt%) 1.921 0.717, 3.125 .003
 BMI (kg/m2) −0.761 −1.157, −0.366 .001
Note: BMI = body mass index; DHA = docosahexaenoic acid; FW = fast walk-
ing; HW = habitual walking; PASE = Physical Activity Scale of the Elderly; 
VJH = vertical jump height.













must be met with learning and repeatability, which may 
have limited our ability to detect treatment effects.
Declines in global measures of cognitive function, ver-
bal memory, and executive function are associated with 
decreases in gait and predict gait speed decline in longitu-
dinal studies (19). Declines in gait speed are also associated 
with impairments of multiple physiological systems (36). 
Overall, these studies and evidence from epidemiological 
studies suggest a range of underlying shared pathological 
processes, such as inflammation, hormonal imbalances, and 
vascular disease, contribute to declines in gait and cogni-
tion (37). It may therefore be that the improved HW speed 
may be related to the improvements in MOT and VRM, 
potentially via beneficial effects on some of these underly-
ing processes. However, further work is needed to explore 
these effects.
Our hypothesis is that a combination of dietary factors 
has superior efficacy over individual nutrients, and success-
ful nutritional interventions may require considerations 
of these synergistic interactions, as has also been found 
by others (38). However, a major unifying factor in the 
intervention is DHA. To identify the contribution of DHA, 
correlations were performed at baseline, where significant 
relationships were seen with DHA and all measures of 
mobility, consistent with previous observations (4). There is 
growing interest in identifying potential blood biomarkers 
for the detection and monitoring of physical performance 
in aging (39), and these results suggest that DHA status 
may provide useful further information.
Correlations between changes in DHA levels and 
changes in mobility and cognition were performed at the 
end of the study, where there were significant associations 
between changes in DHA levels and improvements in mobil-
ity, which were primarily driven by the high-change DHA 
group. This suggests there was a subgroup more responsive 
to the supplementation, consistent with the observations of 
others (40). With cognition, AA:DHA was a stronger pre-
dictor of performance, where there were indications of a 
lower AA:DHA (ie, greater DHA to AA) to perform better 
in the VRM immediate free recall test. The difference in 
prognostic value between DHA levels and AA:DHA may 
depend on which tissue is being examined, and as although 
blood DHA levels show strong correlations with peripheral 
tissues, they may not reflect the composition of the brain 
(41).
The strength of this study is that it was of a rand-
omized, placebo-controlled double-blind design. The high 
retention rate further increased the reliability of the data. 
Furthermore, the study used a range of detailed and sen-
sitive mobility and cognitive tests to assess the treatment 
effects. However, a limitation of the study was that in some 
of the tests, a ceiling effect may have been observed due to 
the high ability of the participants. A further limitation was 
that neither plasma homocysteine levels nor ApoE geno-
types were assessed, which may have affected the partici-
pant’s response to treatment.
Conclusion
In this pilot study, a multinutrient supplement improves psy-
chomotor reaction speed, verbal memory, and HW speed. 
These improvements were clinically relevant and were iden-
tified in able persons. It must be acknowledged that this 
pilot study was not adequately powered for direct compari-
sons between treatment groups, and effects were only seen 
in some of the primary outcomes; however, there were clear 
indications that supplementation improves cognition and 
mobility, which are of major importance in successful aging. 
The study also identified important relationships between 
blood DHA levels and mobility. Further work should seek to 
explore the long-term effects and whether the results can be 
extended to those with cognitive or mobility impairments.
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biomedgerontology.oxfordjournals.org/
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